52169-89-8

Usage

Uses

Used in Pharmaceutical Industry:
4-METHYL-2-PHENYL-1,3-OXAZOLE-5-CARBONYL CHLORIDE is used as a key intermediate in the synthesis of various drugs and biologically active compounds. Its reactive carbonyl chloride group allows for the formation of amide bonds with other molecules, facilitating the creation of new pharmaceutical agents.
Used in Organic Synthesis:
In the field of organic synthesis, 4-METHYL-2-PHENYL-1,3-OXAZOLE-5-CARBONYL CHLORIDE serves as a valuable building block for constructing more complex organic molecules. Its unique structure and reactivity contribute to the development of novel compounds with potential applications in various industries.
Used in Chemical Research:
4-METHYL-2-PHENYL-1,3-OXAZOLE-5-CARBONYL CHLORIDE is also utilized in chemical research as a model compound to study the properties and reactions of oxazole derivatives. Its reactivity and structural features provide insights into the synthesis and modification of related compounds, advancing the understanding of organic chemistry.

InChI:InChI=1/C11H8ClNO2/c1-7-9(10(12)14)15-11(13-7)8-5-3-2-4-6-8/h2-6H,1H3

Upstream product

• 79-37-8 oxalyl dichloride 
• 2198-64-3 N-Benzoylalanine 
• 98-88-4 benzoyl chloride 

Downstream Products

• 248924-06-3 (4-methyl-2-phenyloxazol-5-yl)methanol 

Relevant academic research and scientific papers

Aromatic heterocyclic small molecule organic compounds and derivatives, preparation method and medical use

The invention discloses heterocyclic aromatic micromolecule organic compounds as shown in the structural formula (I) and derivatives thereof, or hydrates or pharmaceutically acceptable salts, and a preparation method of the corresponding compounds; the invention also discloses an application of the compounds and pharmaceutical compositions containing the compounds to the treatment of various metabolic syndrome-related diseases. The heterocyclic aromatic micromolecule organic compounds of the invention have excellent treatment effect on metabolic syndromes; experiment results show that the compounds may promote secretion of endogenous GLP-1, and are applicable to the preparation of anti-diabetic and fat-reducing candidate medicaments. Aiming at technical problems of easy degradation and short half life of current medicaments for treating diabetes, the invention provides novel, high-efficient micromolecule compounds for promoting secretion of endogenous GLP-1, and the compounds are applicable to the treatment of metabolic syndrome-related diseases such as diabetes, obesity and the like.

Discovery and optimization of 2-phenyloxazole derivatives as diacylglycerol acyltransferase-1 inhibitors

In a discovery effort to find safe and effective DGAT-1 inhibitors, we have identified 2-phenyloxazole 4-carboxamide 1 as a conformationally constrained analog of a hydrazide hit, which was previously identified from high-throughput screening. Further optimization of this series has led to chemically more stable 2-phenyloxazole-based DGAT-1 inhibitor 25 with improved solubility, cell-based activity, and pharmacokinetic properties. Compound 25 also demonstrated in vivo efficacy in a diet-induced obesity (DIO) rat model.